Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Merck and Company    MRK

MERCK AND COMPANY (MRK)
Mes dernières consult.
Most popular
  Report  
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nyse
05/16/2018 05/17/2018 05/18/2018 05/21/2018 05/22/2018 Date
59.75(c) 59.07(c) 59.14(c) 58.57(c) 58.45(c) Last
8 531 675 7 845 815 9 686 335 8 475 404 8 928 530 Volume
+0.93% -1.14% +0.12% -0.96% -0.20% Change
More quotes
Financials (USD)
Sales 2018 42 112 M
EBIT 2018 13 641 M
Net income 2018 7 201 M
Debt 2018 15 704 M
Yield 2018 3,33%
Sales 2019 43 350 M
EBIT 2019 14 451 M
Net income 2019 10 153 M
Debt 2019 12 228 M
Yield 2019 3,45%
P/E ratio 2018 22,46
P/E ratio 2019 15,08
EV / Sales2018 4,11x
EV / Sales2019 3,91x
Capitalization 157 B
More Financials
Company
Merck & Co., Inc. engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products.It operates through the following segments: Pharmaceutical, Animal Health, Healthcare Services, and Alliances.The Pharmaceutical... 
Sector
Pharmaceuticals
Calendar
05/22 | 03:00pmShareholder meeting
More about the company
Surperformance© ratings of Merck and Company
Trading Rating : Investor Rating :
More Ratings
Latest news on MERCK AND COMPANY
05/22MERCK : Announces Third-Quarter 2018 Dividend
BU
05/21MERCK AND : Ebola Vaccination Begins in Democratic Republic of Congo -- Update
DJ
05/21MERCK AND : Factbox - From sterling crises to Brexit, the tests of Bank of Engla..
RE
05/21EISAI : To present data on oncology pipeline and products at 54th asco annual me..
AQ
05/21SEATTLE GENETICS : Appoints Roger D. Dansey, M.D., Chief Medical Officer
AQ
05/21EISAI : Announces Data at ASCO 2018 Annual Meeting Showcasing LENVIMA and KEYTRU..
AQ
05/21SYNDAX PHARMACEUTICALS : Announces Updated Results from Phase 2 ENCORE 601 Trial..
AQ
05/21MERCK AND : Ebola Vaccine Arrives in Democratic Republic of Congo
DJ
05/21J&J discontinuing AD trials of BACE1 inhibitor
AQ
05/21WHO : Congo may approve mAb Zmapp for Ebola outbreak
AQ
More news
Sector news : Pharmaceuticals - NEC
08:48aVALEANT PHARMACEUTICALS INTL : Ex-Valeant Executive Convicted In Scheme -- WSJ
DJ
08:16aSHIRE PLC SHIRE PLC : Rule 2.9 Announcement
DJ
05/22VALEANT PHARMACEUTICALS INTL : Ex-Valeant, Philidor executives convicted of kick..
RE
05/22VALEANT PHARMACEUTICALS INTL : Former Valeant Executive Found Guilty on Charges ..
DJ
05/22SHIRE PLC SHIRE PLC : Director Declaration
DJ
More sector news : Pharmaceuticals - NEC
4-Traders Strategies on MERCK AND COMPANY 
MERCK & CO., INC. - 2013
A resistance as obstacle
SELL
More Strategies
Latest Tweets
12:15aJ&J, Pfizer, Merck again lead pharma in Fortune 500: Johnson & Jo.. 
05/22$DRUS MOST VOL iN ITS HISTORY 2DAY? ? $BAC $GE $BMY $WFC $MU $YNDX $AMD $OCL..
1
05/22$DRUS .026 U CAN'T IGNORE THE WHALE BUYS TODAY!?? 52WKLOW!? $BAC $GE $BMY $WF.. 
05/22Competitive Pressure And Lower Demand Will Likely Weigh On Merck's Anti-Infec.. 
05/22$DRUS 026 READ THE TRADES 52WKH 10,000% HIGHER! $BAC $GE $BMY $WFC $MU $YNDX.. 
More tweets
Qtime:347
News from SeekingAlpha
01:52aREADER INQUIRY : Has Tesaro Finally Found A Bottom? 
05/22Merck declares $0.48 dividend 
05/22Entera Bio Re-Enters IPO Process 
05/22European Parliament Will Question Mark Zuckerberg; US/China Trade Tensions Co.. 
05/22WALL STREET BREAKFAST : Zuckerberg Testifies In Brussels 
Chart MERCK AND COMPANY
Duration : Period :
Merck and Company Technical Analysis Chart | MRK | US58933Y1055 | 4-Traders
Technical analysis trends MERCK AND COMPANY
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 21
Average target price 69,1 $
Spread / Average Target 18%
EPS Revisions
Managers
NameTitle
Kenneth C. Frazier Chairman, President & Chief Executive Officer
Robert M. Davis CFO & Executive Vice President-Global Services
Thomas Henry Glocer Independent Director
Rochelle B. Lazarus Independent Director
Leslie A. Brun Lead Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
MERCK AND COMPANY3.87%157 248
JOHNSON & JOHNSON-11.45%333 230
PFIZER-1.16%208 479
NOVARTIS-6.55%202 002
ROCHE HOLDING LTD.-8.90%195 055
AMGEN1.38%116 659